Showing 1331-1340 of 1614 results for "".
- Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-licenses-canadian-rights-to-apotex-for-five-branded-ophthalmic-drugs/2482117/Harrow and Canadian pharma company Apotex jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute Verkazia and over-the-counter (OTC) Cationorm PLUS in the Canadian market, and concurrently, pursue market approval in Canada for Ve
- Sylentis Fails Phase 3 Trial of RNAi-based Drug Candidate for Dry Eye Associated with Sjögren's Syndromehttps://modernod.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/Sylentis, a subsidiary of Spain-based PharmaMar, announced that its phase 3 SYL10111_V (RNAi-based tivanisiran) clinical trial for the treatment of dry eye disease associated with Sjögren’s syndrome did not meet its primary endpoint—the signs and symptoms of DED. T
- Apellis Receives Negative Opinion for Pegcetacoplan for GA in the EU; Plans to Seek Re-Examination of Applicationhttps://modernod.com/news/apellis-receives-negative-opinion-for-pegcetacoplan-for-ga-in-the-eu-plans-to-seek-re-examination-of-application/2482083/Apellis Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to
- Zeiss’ Visumax 800 With Smile Pro Software Approved by FDAhttps://modernod.com/news/zeiss-visumax-800-with-smile-pro-software-approved-by-fda/2482056/Zeiss Medical Technology announced that the FDA has approved the Visumax 800 With Smile Pro software for surgically treating nearsightedness, with or without astigmatism. This latest generation of femtosecond lasers from Zeiss enters the United States market as the technology is being broadly ado
- Eylea 8 mg Approved in EUhttps://modernod.com/news/eylea-8-mg-approved-in-eu/2482046/The European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME).
- Visiox Pharmaceuticals to be Listed on Nasdaq Through Combination with PowerUp Acquisitionhttps://modernod.com/news/visiox-pharmaceuticals-to-be-listed-on-nasdaq-through-combination-with-powerup-acquisition/2482029/Visiox Pharmaceuticals and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market. The business combination is expected to close in the first quarter of
- Cell Types in the Eye Have Ancient Evolutionary Originshttps://modernod.com/news/cell-types-in-the-eye-have-ancient-evolutionary-origins/2482026/Karthik Shekhar of the Shekhar Lab at UC Berkeley and his colleagues raised a few eyebrows as they collected cow and pig eyes from Boston butchers, but those eyes—eventually from 17 separate species, including humans—are providing insights into the evolution of the vertebrate ret
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- Injectsense and Injectpower Secure $9.4M to Support Injectsense's First-in-Human Studies for Sensors that Continuously Measure IOPhttps://modernod.com/news/injectsense-and-injectpower-secure-94m-to-support-injectsenses-first-in-human-studies-for-sensors-that-continuously-measure-iop/2481973/Injectsense and sister company Injectpower, a developer of ultra-miniature solid-state microbatteries for medical applications, announced combined funding of $9.4 million to bring highly integrated autonomous implantable devices—smaller than a grai
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien